Product Images Fulvestrant

This appears to be a chart displaying the progression-free survival of patients in a study comparing the effectiveness of two doses of Fulvestrant, 250mg and 500mg. The graph includes the number of patients at risk and the time frame in months.*

This appears to be a graph or chart depicting the effectiveness of two different doses of a drug called Fulvestrant over a period of 80 months. The two doses are 500 mg and 250 mg, and the chart shows the number of patients at risk for each dosage at different time intervals. There seems to be no significant difference between the effectiveness of the two doses, as no adjustments were made for multiplicity. The tick marks indicate censored observations.*

This is a table showing the progression-free survival probability of patients who were given a combination of Fulvestrant and Palbociclib or a combination of Fulvestrant and placebo, over a period of 14 months. However, there is not enough information to draw any conclusions without further contextual information.*

This text presents the results of a study comparing two drug combinations, "Fulvestrant+palbociclib" and "Fulvestrant+placebo", on Overall Survival Probability (%) over a period of 54 months. The text also includes a chart with the number of patients at risk over time.*

This is a graph showing the results of a clinical trial comparing the effectiveness of two treatments for a medical condition using Fulvestrant plus Abemaciclib and Fulvestrant plus Placebo. The trial involved 446 patients in the Fulvestrant plus Abemaciclib group and 223 patients in the Fulvestrant plus Placebo group. The X-axis represents time in months and the Y-axis indicates the percentage of patients still alive or without disease progression. The graph depicts that the group that received Fulvestrant plus Abemaciclib reported a higher percentage of patients without disease progression than the Fulvestrant plus Placebo group.*

The provided text consists of survival analyses of patients under two different treatments. The first treatment is Fulvestrant plus Abemaciclib, which was given to 446 patients and the second treatment is Fulvestrant plus Placebo, which was given to 223 patients. The curve shows the number of patients remaining over time (in months) for each treatment group, where the y-axis represents the percentage of patients still receiving treatment and the x-axis shows the number of months. The graph shows censoring periods at specific months where observations are not included.*

This graph displays the survival rates of the two treatments of Fulvestrant, one with ribociclib (N=484) and another with a placebo (N=242), over the course of 48 months. The Y-axis displays the number of patients still at risk, and the X-axis displays the time in months. The line for Fulvestrant with ribociclib begins at 484 and ends at zero, representing zero patients after 48 months, and has a steady decline. The graph for Fulvestrant with placebo shows the same steady decline, starting at 242 and reaching zero after 48 months.*